The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Plasma exosome microRNA-155 expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A potential biomarker of response to systemic therapy.
 
Maryam Soleimani
Honoraria - Pfizer
Research Funding - Abbvie (Inst); Bayer
 
Marisa Thi
No Relationships to Disclose
 
Neetu Saxena
No Relationships to Disclose
 
Bernhard J. Eigl
Honoraria - AstraZeneca; Janssen; Merck; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca; Janssen; Merck; Roche Canada
 
Daniel Joseph Khalaf
Honoraria - Janssen
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Ipsen; Merck; Merck KGaA; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer
 
Lucia Nappi
Honoraria - Astellas Pharma; Ipsen; Pfizer
Patents, Royalties, Other Intellectual Property - IVERMECTIN ANALOGUE COMPOUND THERAPEUTICS FOR HEAT SHOCK PROTEIN-27 (HSP27) INHIBITION, METHODS AND USES ASSOCIATED THEREWITH provisional number: 62/756,707
Travel, Accommodations, Expenses - Pfizer